Chile strengthens disease surveillance as global health alerts rise over measles, dengue, and Ebola

Chile's health system is running on high alert. In late May, as measles cases climbed in Peru and Ebola spread through Uganda and the Democratic Republic of Congo, the country's disease surveillance machinery shifted into a more vigilant gear—not out of panic, but out of the practiced caution that comes from living in a globalized world where a virus in one country can become a problem in another within days.

Gabriela Morgado, an infectious disease researcher at Andrés Bello University's Institute for Health Care Research, laid out the stakes plainly. Chile has built something most countries envy: a free, universal immunization program that is recognized internationally, paired with epidemiological surveillance systems capable of spotting suspicious cases early, tracking contacts, and triggering coordinated health responses. These are not new systems. They have been tested. But they are being tested again.

Measles is the most immediate concern. Peru's outbreak has reignited international alarm, particularly among the unvaccinated. Chile itself has not seen endemic measles since 1993—a victory won through sustained vaccination campaigns. Every case detected in the country since then has been imported from elsewhere. The most recent one arrived in January 2026. But that victory is fragile. The national immunization schedule calls for one dose at age one and a second at age three. In 2025, 93 percent of one-year-olds received their first shot. Only 75 percent of three-year-olds got their second. That gap matters. Morgado emphasized that people born between 1971 and 1981 who lack documented proof of two doses after age twelve should get a booster. The virus does not care about decades-old immunity; it cares about whether you are protected now.

Beyond measles, Chile is managing a constellation of threats. Dengue has established a foothold on Easter Island, where the Aedes aegypti mosquito has lived since 2000. In 2026 alone, the island recorded 22 locally transmitted cases alongside 14 imported ones elsewhere in the country. The mosquito has also returned to northern cities like Arica and Iquique, and was detected in Los Andes in 2023. The disease spreads through a vector that is difficult to eliminate once it takes hold.

Hantavirus presents a different kind of problem. There is no vaccine. The virus lives in the long-tailed mouse and spreads when people inhale particles from the animal's urine, saliva, or droppings. In 2026, Chile recorded 39 cases with a fatality rate near 33 percent—worse than the previous year. A cluster even appeared on a cruise ship, traced to the Andes strain that circulates in both Chile and Argentina. Without a vaccine, prevention and education are the only tools. Morgado was clear on this: the disease remains complex precisely because medicine cannot yet offer immunity.

Ebola looms larger in the global consciousness than in Chile's immediate risk calculus. The World Health Organization declared the current outbreak in Uganda and the Democratic Republic of Congo a public health emergency of international concern. The strain circulating there is highly transmissible with a fatality rate around 30 percent. Population displacement and limited health access in affected zones raise the specter of regional spread. Morgado explained that Ebola has historically stayed in Africa; the few cases outside the continent have involved health workers who were directly exposed during outbreaks. Chile faces no direct threat today.

But that qualifier—today—carries weight. Morgado's closing observation cut to the heart of why Chile is maintaining this vigilance: in a world where people move constantly and new viruses emerge without warning, the systems of prevention and surveillance must be permanently strengthened. The country's robust infrastructure gives it an advantage in detecting imported cases early. The question is whether that infrastructure can stay ahead of the speed at which disease now travels.